Noninvasive optical imaging is an increasingly critical technology for R&D.
Novartis signed a multiyear license deal with Caliper Life Sciences’ related to its noninvasive optical imaging methods.
Noninvasive optical imaging allows scientists to visualize, track, and quantify biological processes at the molecular level in living animals with high throughput and relatively low cost, according to Caliper.
“This multiyear agreement further validates the importance and relevance of Caliper’s optical imaging technology and intellectual property,” remarks Kevin Hrusovsky, CEO at Caliper Life Sciences.
“More than 70% of major pharmaceutical companies, and 60% of major biotech companies now hold a license to the Caliper optical imaging patent suite, and smaller biotechs are following suit in increasing numbers,” Hrusovsky adds.
